Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 open label, study to determine the safety, efficacy and pharmacokinetic profile of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne Muscular Dystrophy.

Trial Profile

A Phase 2 open label, study to determine the safety, efficacy and pharmacokinetic profile of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne Muscular Dystrophy.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATL 1102 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 18 Nov 2019 According to an Antisense Therapeutics media release, dosing in all patients to be completed this month.
    • 18 Nov 2019 Additional preliminary data published in an Antisense Therapeutics Media Release
    • 18 Nov 2019 According to an Antisense Therapeutics media release, additional preliminary data analyses from the seven patients who have completed their 24 weeks of dosing in this trial was presented by Dr Ian Woodcock at the 2019 Action Duchenne International Conference 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top